title: Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer.
abstract: OBJECTIVE
  The purpose of this study was to demonstrate the dosimetric and clinical feasibility of image guided radiation therapy (IGRT) combined with high-dose-rate (HDR) intracavitary brachytherapy (ICBT) to improve dose distribution in cervical cancer treatment.
  
  
  METHODS
  For 42 cervical cancer patients, magnetic resonance imaging (MRI) scans were acquired after completion of whole pelvic irradiation 45-46 Gy and 5 fractions of B + I (ICBT + IGRT) treatment were subsequently received. The high risk clinical target volume (HRCTV), intermediate risk clinical target volume (IRCTV), bladder, rectum, and sigmoid were contoured on the computed tomography (CT) scans. The total planning aim doses for HRCTV was D90% > 85 Gy, whilst constraints for rectum and sigmoid were D2cc < 75 Gy and D2cc < 90 Gy for bladder in terms of an equivalent dose in 2 Gy (EQD2) for external beam radiotherapy (EBRT) and brachytherapy boost. The IGRT plan was optimized on top of the ICBT dose distribution. A dosimetric comparison was made between B + I and optimized ICBT (O-ICBT) only.
  
  
  RESULTS
  The mean D90% of HRCTV was comparable for B + I and O-ICBT (p = 0.82). For B + I plan, HRCTV D100%, IRCTV D100%, and IRCTV D90% were significantly increased by a mean of 10.52 Gy, 5.61 Gy, and 2.70 Gy, respectively (p < 0.01). The D2cc for bladder, rectum, and sigmoid were lower by a mean of 21.36, 6.78, and 10.65 Gy, respectively (p < 0.01). The mean rectum V60 Gy value over 42 patients was almost the same for both techniques but for bladder and sigmoid B + I had higher V60 Gy mean values as compared with the O-ICBT.
  
  
  CONCLUSIONS
  B + I can improve dose distribution in cervical cancer treatment; it could be useful for tumors extended beyond the reach of intracavitary/interstitial brachytherapy (IC/ISBT) or for centers that are inexperienced or ill-equipped with IC/ISBT techniques. Additional confirmatory prospective studies with larger numbers of patients and longer follow-up are required to validate the durability.
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.
authors.forename: Xianliang
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.
authors.forename: Pei
authors.initials: P
authors.lastname: Wang
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Yuan
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Yin
authors.affiliation: Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Wan
keywords: HDR brachytherapy; IGRT; cervical cancer